United Therapeutics Corp
(
UTHR)
Tyvaso DPI (NDA)
Oct 2021
FDA decision on Tyvaso DPI for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease
FDA issued a Complete Response Letter for Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease on Oct.15, 2021-
Tyvaso DPI (NDA)
Oct 2021
FDA decision on Tyvaso DPI for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease
FDA issued a Complete Response Letter for Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease on Oct.15, 2021-
Gilead Sciences Inc.
(
GILD)
Tecartus (sBLA)
10/01/2021
FDA decision on Tecartus for the treatment of adult patients with relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia
FDA approves Tecartus for adults with relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia on Oct. 1,2021-